SOT-107

DB05337InvestigationalProtein Based Therapies

SOT-107 is a drug that is a combination of a protein called transferrin and a poison called diphtheria toxin. This drug treat for a type of brain cancer called a... About half of all brain tumours are gliomas.

Mechanism: Its mechanism of action involves transferrin-mediated delivery of a modified diphtheria toxin that is capable of selectively killing cancer cells. The agent is administered directly into the glioma using convection enhanced delivery to circumvent the blood-brain barrier and achieve high local concentrations of the drug.
Curator reviewed
Primary indication: Investigated for use/treatment in brain cancer.Curator reviewed
Also known as: Transferrin-CRM 107
Code names: CRM 107 · TF CRM 107 · XR 311

Resolves to

Targets

P48060GLIPR1

What you can answer from here — as of December 03, 2022

1Protein targetEach mapped to UniProt, with action and pharmacological action

Listed above

3Clinical trialsPhase, status and sponsor resolved per trial

1+ReferenceStructured and connected to the statements they support

Which drugs share a target with SOT-107, and which of those have an active Phase 3 trial?

Answer this in Biopharma OS Sign in to your account

Create a free account or log in to explore the full data card.

Create Account